Integrated Filing — IndAS



General information about company
Scrip Code 539872
NSE Symbol BAJAJHCARE
MSEI Symbol NOTLISTED
ISIN INE411U01027
Name of company BAJAJ HEALTHCARE LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 26-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 20-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 26-May-2025   16:10:00
End date and time of board meeting 26-May-2025   16:52:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-11
Indicate Company website link for updated RPT policy of the Company https://www.bajajhealth.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
During the period ended 31.03.2025, there is no default.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1544725000 5426024000
Other income 135716000 194044000
Total income 1680441000 5620068000
2 Expenses
(a) Cost of materials consumed 1004909000 3071090000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -65223000 -206637000
(d) Employee benefit expense 157060000 570583000
(e) Finance costs 60758000 279044000
(f) Depreciation, depletion and amortisation expense 75310000 279178000
(f) Other Expenses
1 Other Expenses 330407000 1166733000
Total other expenses 330407000 1166733000
Total expenses 1563221000 5159991000
3 Total profit before exceptional items and tax 117220000 460077000
4 Exceptional items 0 0
5 Total profit before tax 117220000 460077000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 1290000 30789000
9 Total tax expenses 1290000 30789000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 115930000 429288000
12 Profit (loss) from discontinued operations before tax -8803000 -40111000
13 Tax expense of discontinued operations -4651000 -5778000
14 Net profit (loss) from discontinued operation after tax -4152000 -34333000
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 111778000 394955000
17 Other comprehensive income net of taxes 34517000 13701000
18 Total Comprehensive Income for the period 146295000 408656000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 157916000 157916000
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 3.67 14.45
Diluted earnings (loss) per share from continuing operations 3.59 14.26
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -0.13 -1.16
Diluted earnings (loss) per share from discontinued operations -0.13 -1.14
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.54 13.29
Diluted earnings (loss) per share from continuing and discontinued operations 3.46 13.12
24 Debt equity ratio 0.0048 0.0048
25 Debt service coverage ratio 0.0044 0.0044
26 Interest service coverage ratio 0.0365 0.0365
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) ttttt n3. The above audited financial results for the Year Ended 31 March 2025 have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards Ind AS,as prescribed under Section 133 of the Companies Act 2013 Act read with relevant rules issued there under and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing obligations and disclosure requirements Regulations,2015 as amended.ttttttt nttttt n4. The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.ttttt1. The above Financial Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 26 May 2025.ttttt nttttt nttttt n2. The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year.t nttttt n nttttt nttttt n5. In the previous financial year ended 31 March 2024, the Board of Directors had approved to sale or disposal of undertaking or units on going concern basis, situated at plot no. N92, L 9 3 , T30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 and D 2 CH 43 Dahej industrial area, GIDC, Bharuch, Gujarat which were acquired under SARFAESI ACT, 2022 from Saraswat Bank and plot no. E 62 and E 63 MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale or disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the statement of profit and loss as discontinued operations. Considering these assets are held for sale, the assets have been recorded at their fair value on the date these assets has been classified as held for sale. Out of these, one unit situated at plot no. N92 was sold during the Quarter ended 31 March 2024. The total value of assets classified as held for sale represents lower of carrying value or fair value.ttttt nttttt nThe financial information from discontinued operations:ttttt nParticularstQuarter EndedtttYear Endedt nt31 March 2025t31 Dec 2024t31 March 2024t31 March 2025t31 March 2024 nTotal Income A t 37.81 t 65.40 t 380.70 t 58.07 t 1,784.51 nTotal Expenses B t 50.22 t 183.13 t 1,720.79 t 459.18 t 10,503.47 nLoss before Tax from Discontinued Operations t 88.03 t 117.73 t 1,340.09 t 401.11 t 8,718.96 nTax Expense Credit from Discontinued Operations D t 46.51 t 206.71 t 1,547.70 t 57.78 t 1,772.31 nLoss after Tax from Discontinued Operationst 41.52 t 324.44 t 207.61 t 343.33 t 6,946.65 nttttt n6. The Board of Directors the Company in their meeting held on 10 July 2024 and the shareholders of the company in ExtraOrdinary General Meeting EGM held on Wednesday, 07 August, 2024 through Video Conferencing VC or Other Audio Visual Means OAVM approved, the issue of 40,44,852 Equity Shares at Rs 338 per share to Person s belonging to non promoter category on preferential basis and the issue of convertible equity warrants 20,79,409 at Rs. 338 to Person s belonging to promoter category as well as non promoter category on preferential basis. The object of the issue is to repayment of term loan, investment in capital expenditure and general corporate purpose. The Company has also obtained the in principal approval of listing of equity shares from National Stock Exchange of India Ltd and BSE Ltd. On 19 September 2024, post approval from Board, the Company has alloted 39,84,852 no. of equity shares and has also filed the relevant form with Registrar of Companies. The uncalled amount of share warrants as at 31 March 2025 is Rs. 5,271.30 lakhs.ttttt nttttt ntttttttt n7. The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities.ttttt nParticularstttttRs. in Lakhs nRepayment and prepayment of secured or unsecured loans from bank and NBFCttttt 15,000.00 nGeneral corporate purposettttt 225.90 nTotalttttt 15,225.90 nttttt n8. During the previous year, the Company had written off inventories pertaining to certain covid portfolio products owing to continued lower demand, on a conservative basis.ttttt nttttt nttttt n9. Subsequent to the year ended 31 March 2025, the Company acquired Genrx Pharmaceuticals Private Limited which was under liquidation on a going concern basis.ttttt nttttt nttttt n10. The Board of Directors have recommended a Final dividend of 20% i.e. Rs. 1.00 Only per equity share on the face value of Rs. 5 each for the financial year ended 31 March 2025, subject to approval of shareholders in the ensuing Annual General Meeting. ttttt nttttt n11. Previous year or period figures have been regrouped to make them comparable with the current year or period figures, which are not material.ttttt n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2365594000
Capital work-in-progress 34485000
Investment property 0
Goodwill 0
Other intangible assets 18887000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 33000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 56085000
Total non-current financial assets 56118000
Deferred tax assets (net) 188952000
Other non-current assets 57298000
Total non-current assets 2721334000
2 Current assets
Inventories 1618877000
Current financial asset
Current investments 0
Trade receivables, current 2516742000
Cash and cash equivalents 26038000
Bank balance other than cash and cash equivalents 18470000
Loans, current 0
Other current financial assets 334318000
Total current financial assets 2895568000
Current tax assets (net)
Other current assets 339585000
Total current assets 4854030000
3 Non-current assets classified as held for sale 755098000
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 8330462000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 157916000
Other equity 4503726000
Total equity attributable to owners of parent 4661642000
Non controlling interest
Total equity 4661642000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 646651000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 2540000
Total non-current financial liabilities 649191000
Provisions, non-current 49810000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total non-current liabilities 699001000
Current liabilities
Current financial liabilities
Borrowings, current 1579591000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 84401000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 870330000
Total Trade payable 954731000
Other current financial liabilities 104966000
Total current financial liabilities 2639288000
Other current liabilities 70741000
Provisions, current 12633000
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 2722662000
3 Liabilities directly associated with assets in disposal group classified as held for sale 247157000
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 3668820000
Total equity and liabilites 8330462000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments Textual Information(2)



Text Block
Textual Information(2) The Company deals in pharmaceuticals products (formulations and active pharmaceutical ingredients components) which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals.



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to profit or loss 46127000 18309000
Total Amount of items that will not be reclassified to profit and loss 46127000 18309000
2 Income tax relating to items that will not be reclassified to profit or loss 11610000 4608000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 34517000 13701000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 460077000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 279044000
Adjustments for decrease (increase) in inventories -178495000
Adjustments for decrease (increase) in trade receivables, current -683280000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 110204000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances -5099000
Adjustments for increase (decrease) in trade payables, current 0
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 0
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 279178000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 129446000
Adjustments for unrealised foreign exchange losses gains -38562000
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) -40111000
Other adjustments for non-cash items -50338000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -198013000
Net cash flows from (used in) operations 262064000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 45859000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 216205000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 1100000
Purchase of property, plant and equipment 115385000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 5059000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -38925000
Net cash flows from (used in) investing activities -148151000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 1496975000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 450000000
Repayments of borrowings 1702805000
Payments of lease liabilities 1291000
Dividends paid 27598000
Interest paid 279044000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -63763000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 4291000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents 4291000
Cash and cash equivalents cash flow statement at beginning of period 21747000
Cash and cash equivalents cash flow statement at end of period 26038000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Walker Chandiok Co & LLP Yes 31-May-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Bajaj Healthcare Limited Mr. Sajankumar Bajaj Chairman & Managing Director Remuneration NA 19748000 0 0
2 Bajaj Healthcare Limited Mr. Anil Jain Managing Director Remuneration NA 13748000 0 0
3 Bajaj Healthcare Limited Mr. Dhanajay Hatle Whole-Time Director Remuneration NA 1824000 0 0
4 Bajaj Healthcare Limited Ms. Namrata Bajaj Whole-Time Director Remuneration NA 862000 0 0
5 Bajaj Healthcare Limited Mr. Pakshal Jain Whole-Time Director Remuneration NA 1164000 0 0
6 Bajaj Healthcare Limited Mr. Hemant Karnik Non-Executive Independent Director Any other transaction Sitting Fees for Board & Committee Meetings NA 93000 0 0
7 Bajaj Healthcare Limited Mr. Ram Banarse Non-Executive Independent Director Any other transaction Sitting Fees for Board & Committee Meetings NA 88000 0 0
8 Bajaj Healthcare Limited Mr. Sandeep Shah Non-Executive Independent Director Any other transaction Sitting Fees for Board & Committee Meetings NA 35000 0 0
9 Bajaj Healthcare Limited Mr. Yaqoob Ali Non-Executive Independent Director Any other transaction Sitting Fees for Board & Committee Meetings NA 0 0 0
10 Bajaj Healthcare Limited Mrs. Kejal Shah Non-Executive Independent Director Any other transaction Sitting Fees for Board & Committee Meetings NA 15000 0 0
11 Bajaj Healthcare Limited Mrs. Nihita Bajaj Kumar Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time Director Any other transaction Legal & Professional Fees 1500000 Approved by the Audit Committee 600000 0 0
12 Bajaj Healthcare Limited Ms. Khushi Jain Daughter of Mr. Anil Jain, Managing Director & Sister of Mr. Pakshal Jain, Whole-Time Director Any other transaction Legal & Professional Fees 1200000 Approved by the Audit Committee 300000 0 0
13 Bajaj Healthcare Limited Mrs. Dhanshree D Hatle Wife of Mr. Dhananjay Hatle, Whole-Time Director Any other transaction Legal & Professional Fees 500000 Approved by the Audit Committee 231000 0 0
14 Bajaj Healthcare Limited Mrs. Harshavi Pakshal Jain Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing Director Remuneration NA 866000 0 0
15 Bajaj Healthcare Limited Mr. Sajankumar Bajaj Chairman & Managing Director Loan 500000000 Approved by the Audit Committee 12500000 528000 528000 Loan 0 5years Unsecured Corporate Business Purposes
16 Bajaj Healthcare Limited Ms. Apurva Bandivadekar Company Secretary (Resigned as on 31.01.2025) Remuneration NA 117000 0 0
17 Bajaj Healthcare Limited Mr. Dayashankar Patel Chief Financial Officer (Resigned as on 15.04.2025) Remuneration NA 1145000 0 0
18 Bajaj Healthcare Limited Ms. Monica Tanwar Company Secretary (Appointed as on 11.02.2025) Remuneration NA 119000 0 0
Total value of transaction during the reporting period 53455000